Therapy of netakimab in nail psoriasis

Abstract

Introduction. The nail psoriasis severity does not always correspond to the skin process intensity, but often correlates with a more severe, prolonged and aggressive course of the disease.Materials and methods. 48 adult patients (n = 48) with nail psoriasis were under observation. The severity of the psoriatic lesion of the nails was determined using the NAPSI index (Nail Psoriasis Severity Index). The assessment was carried out before the start of treatment, in the first week, and then every 4 weeks up to and including 52 weeks. The Dermatological Quality of Life Index (DLQI) were determined by questionnaires before the start of treatment, at the 12th and 52nd weeks. All patients on an outpatient basis received netakimab monotherapy at a dose of 120 mg in the form of two subcutaneous injections of 1 ml (60 mg) of the drug, each administered once a week at weeks 0, 1 and 2, then 1 time every 4 weeks. The total duration of treatment for each patient was 52 weeks. The safety of netakimab was evaluated based on the development of adverse events and local reactions to the administration of the drug.Results. The results of the study for 52 weeks showed high efficacy of netakimab. Average NAPSI score improved – 33.1% by the week 12 of treatment and – 72.3% by the week 52 compared to baseline, the quality of their life improved. During the 52 weeks of the study, there were no cases of early withdrawal due to adverse events and cases of serious adverse events.Conclusion. Based on the study results we recommend netakimab for medical use among patients with moderate and severe nail psoriasis.